Daniel Klamer

Daniel Klamer is the Vice President of Business Development and Scientific Strategy at Anavex Life Sciences. Daniel has over 10 years of experience in the pharmaceutical industry, with a focus on business development and scientific strategy.

Daniel Klamer began their career as a post-doc/senior researcher at the Department of Pharmacology at the Sahlgrenska Academy at University of Gothenburg, where they investigated cognitive impairments in psychiatric diseases. Daniel then spent three years as a business development analyst at Retrophin, where they played a central role in identifying strategic buying and partnering opportunities within a tight timeframe.

In 2013, Klamer joined Intellect Neurosciences, Inc. as a senior scientist and project leader. Daniel spent one year at NeuroSearch as a senior research scientist before joining Anavex Life Sciences in 2014.

Daniel Klamer completed a Master of Business Administration (MBA) with a focus in finance from Fordham Gabelli School of Business. Daniel then went on to complete a PhD in pharmacology from University of Gothenburg. Daniel is currently a visiting scholar in the Department of Psychiatry at UC San Diego.

Daniel Klamer reports to Christopher Missling, President & CEO. Daniel Klamer works with Walter E Kaufmann - Chief Medical Officer, Stephan Toutain - Senior Vice President of Operations, and Emmanuel O Fadiran - Senior Vice President of Regulatory Affairs .